Cure8 research brief
This bibliometric analysis summaries recent Spanish research activity in IBD, showing where work is concentrated, the mix of clinical versus basic/translational studies, and gender representation in scientific leadership—information that can matter for researchers, clinicians, and patients interested in the national research ecosystem and collaboration opportunities.
Researchers, IBD clinicians in Spain (and collaborators), research funders, and patients or patient advocates interested in the national research landscape and equity in research leadership.
This paper provides a descriptive overview of Spanish IBD research output from 2020–2024, analysing publication counts, study types (clinical vs basic/translational), regional distribution, journal impact (quartiles), use of advanced experimental methods, and authorship characteristics including gender and scientific leadership.
It also summarises Spanish representation among accepted abstracts at ECCO meetings from 2019–2024. The study found 1,361 Spanish IBD publications in the period, with about 61% clinical and 39% basic/translational work, most appearing in higher-quartile journals.
Research activity was concentrated in Catalonia and Madrid, advanced methodologies were commonly used in basic/translational studies, and women had greater representation in leadership roles within basic/translational research compared with clinical studies.
The article is a descriptive analysis based on PubMed-indexed publications (2020–2024) and ECCO abstract data (2019–2024). It summarizes publication patterns and authorship characteristics rather than presenting new experimental or clinical trial findings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
